Selecta turns to synbio player for $1.1B capsid deal; BioNTech signs $790M immunotherapy deal
Selecta Biosciences has turned to one of the recent darlings in the synbio biz for its latest collaboration.
Ginkgo Bioworks has signed on to a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
